Analysts expect Jade Biosciences, Inc. to report revenue of 0.00 for Q2 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q1 26, came in at 0.00.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - |
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Jade Biosciences, Inc. to report earnings per share of -0.61 for Q2 26, against a range of -0.66 to -0.56. The most recent reported quarter, Q1 26, came in at -0.57, a 14.0% miss against the -0.50 consensus.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -30.10 | -19.60 | -6.65 | -12.10 | -0.86 | -0.48 | -0.45 | -0.57 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | -24.71 | -14.95 | -5.72 | -6.24 | -0.41 | -0.62 | -0.47 | -0.48 | -0.56 | -0.65 | -0.69 | -0.62 | 5.25 | 5.22 | 4.00 | -5.60 | |||||||||||
| Low Estimate | -28.83 | -16.37 | -6.64 | -6.64 | -0.47 | -0.66 | -0.51 | -0.52 | -0.66 | -0.73 | -0.77 | -0.70 | 4.45 | 4.88 | 3.30 | -6.40 | |||||||||||
| Consensus Estimate | -26.77 | -15.66 | -6.18 | -6.44 | -0.44 | -0.64 | -0.49 | -0.50 | -0.61 | -0.69 | -0.73 | -0.66 | 4.85 | 5.05 | 3.65 | -6.00 |